Also, based on the key cellular functions of cyclin D1 in driving cell cycle progression, we further propose that downregulation of cyclin D1 by zotatifin contributes to the strong anti-tumor activity of zotatifin and to the effectiveness of combination treatments with PI3K or AKT inhibitors. The gene discussed is AKT1; the disease is neoplasm.